CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial

詳細情報 詳細情報について

• CRID

  1360017286990455424

• DOI

  10.1016/s2352-3026(21)00134-4

• ISSN

  23523026

• Web Site

  https://api.elsevier.com/content/article/PII:S2352302621001344?httpAccept=text/xml

  https://api.elsevier.com/content/article/PII:S2352302621001344?httpAccept=text/plain

• データソース種別

  • Crossref